Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Arcus Biosciences, Inc.

Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to help people with cancer live longer. Located in the San Francisco bay area, Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus has an ambitious undertaking and expects to become a force in the discovery, development and commercialization of novel combination therapies to treat cancer in areas of high unmet need. Our employees enjoy operating in an exceptionally dynamic and team-driven environment in which the “rule book” has not yet been written.

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue		1.41M -	8.35M 491.15%	15M 79.58%	77.52M 416.78%	382.88M 393.93%	112M 70.75%	117M 4.46%
cost of revenue				78.48M -	159M 102.60%	7.06M 95.56%	14M 98.38%	16M 14.29%
gross profit		1.41M -	8.35M 491.15%	-63.48M 859.98%	-81.48M 28.36%	375.82M 561.23%	98M 73.92%	101M 3.06%
selling and marketing expenses
general and administrative expenses	3.94M -	7.64M 94.05%	13.57M 77.66%	25.23M 85.96%	42.40M 68.08%	72.29M 70.47%	104M 43.87%	117M 12.50%
selling general and administrative expenses	3.94M -	7.64M 94.05%	13.57M 77.66%	25.23M 85.96%	42.40M 68.08%	72.29M 70.47%	104M 43.87%	117M 12.50%
research and development expenses	14.25M -	47.22M 231.42%	49.65M 5.14%	78.48M 58.08%	159.35M 103.04%	256.35M 60.87%	288M 12.35%	340M 18.06%
other expenses
cost and expenses	18.18M -	54.85M 201.69%	63.21M 15.24%	103.71M 64.07%	201.75M 94.54%	328.63M 62.89%	392M 19.28%	457M 16.58%
operating expenses	18.18M -	54.85M 201.69%	63.21M 15.24%	103.71M 64.07%	201.75M 94.54%	328.63M 62.89%	392M 19.28%	457M 16.58%
interest expense			4.92M -			260K -	2M 669.23%	2M 0%
ebitda	-16.87M -	-50.83M 201.33%	-56.09M 10.35%	-88.71M 58.16%	-124.85M 40.74%	54.91M 143.98%	-264M 580.83%	-291M 10.23%
operating income	-18.18M -	-53.44M 193.92%	-54.86M 2.65%	-88.71M 61.70%	-124.23M 40.05%	54.25M 143.67%	-280M 616.15%	-340M 21.43%
depreciation and amortization	1.31M -	2.61M 98.78%	3.66M 40.28%	3.58M 2.35%	-613K 117.13%	657K 207.18%	16M 2,335.31%	8M 50%
total other income expenses net	212K -	359K 69.34%	343K 4.46%	4.00M 1,065.89%	1.38M 65.57%	397K 71.17%	14M 3,426.45%	39M 178.57%
income before tax	-17.97M -	-53.08M 195.39%	-49.59M 6.57%	-84.71M 70.81%	-122.86M 45.03%	54.65M 144.48%	-266M 586.78%	-301M 13.16%
income tax expense			5.26M -	-8.78M 266.74%	-6.18M 29.59%	1.81M 129.36%	1M 44.90%	6M 500%
net income	-17.97M -	-53.08M 195.39%	-49.59M 6.57%	-75.93M 53.11%	-116.68M 53.66%	53M 145.42%	-267M 603.77%	-307M 14.98%
weighted average shs out	24.55M -	42.55M 73.29%	34.62M 18.64%	43.83M 26.60%	54.79M 25.01%	69.35M 26.57%	72M 3.83%	74M 2.78%
weighted average shs out dil	24.55M -	42.55M 73.29%	34.62M 18.64%	43.83M 26.60%	54.79M 25.01%	73.97M 35.01%	72M 2.66%	74M 2.78%
eps	-0.73 -	-1.25 71.23%	-1.43 14.40%	-1.73 20.98%	-2.13 23.12%	0.76 135.68%	-3.71 588.16%	-4.15 11.86%
epsdiluted	-0.73 -	-1.25 71.23%	-1.43 14.40%	-1.73 20.98%	-2.13 23.12%	0.71 133.33%	-3.71 622.54%	-4.15 11.86%

COM:ARCUSBIO

Arcus Biosciences

Last Close

14.98

26/07 20:00

Market Cap

1.27B

Beta: -

Volume Today

433.94K

Avg: -

Preview